Cardiotoxicity is potentially the most threatening nonhaematological side effect of high-dose CY. We prospectively evaluated the very acute cardiac effects of high-dose CY in 17 adult non-Hodgkin's lymphoma (NHL) patients receiving CY 1500 mg/m 2 /day as a part of BEAC high-dose therapy (HDT). Magnetic resonance imaging (MRI) and plasma natriuretic peptide (NT-proBNP, NT-proANP) measurements were performed prior to HDT (d-7) and just after completing HDT (d-2). After the high-dose CY left atrial end-systolic area increased from 15.271.2 to 18.571.4 cm 2 (P ¼ 0.001), left ventricular end-diastolic volume from 136.1712.3 to 156.6711.1 cm 3 (P ¼ 0.04) and left ventricular end-systolic volume from 67.477.8 to 75.377.1 cm 3 (P ¼ 0.018). However, no significant change in left ventricular ejection fraction (LVEF) was observed. At the same time, plasma levels of NT-proBNP increased from 134.9753.3 to 547.17168.4 pmol/l (P ¼ 0.003) and NT-proANP from 481.17105.5 to 1056.67193.1 pmol/l (P ¼ 0.001), respectively. To conclude, high-dose CY results in very acute cardiac toxicity characterised by enlargement of the heart chambers in NHL patients previously treated with anthracyclines. This toxicity can be detected with increased concentrations of circulating natriuretic peptides but not with LVEF measurement.
Non-Hodgkin's lymphoma (NHL) is currently among the leading indications for high-dose therapy (HDT) supported by autologous stem-cell transplantation (ASCT). 1 HDT is associated with both acute and long-term toxicities. The use of high-dose CY in the conditioning regimens has been considered to be the main cause of cardiac toxicity of HDT protocols. This toxicity may present clinically as myocarditis, congestive heart failure and even sudden death. [2] [3] [4] [5] These complications most often occur within a few weeks after high-dose CY, but they may be detectable already a few days after the treatment. [6] [7] [8] [9] Limited data are available on very acute cardiac toxicity of high-dose CY containing regimens in NHL patients. 10 The prohormones of A-and B-type natriuretic peptides are produced by cardiac myocytes and cleaved on secretion into biologically active peptides (ANP and BNP) and their N-terminal counterparts (NT-proANP and NT-proBNP). Natriuretic peptide measurements have been used to monitor cardiotoxicity during or after stem cell transplantation. 11, 12 However, in these studies any clear conclusion about very acute cardiotoxicity cannot been drawn because assessment of cardiac function was not performed until weeks after HDT. These studies also were heterogeneous in terms of patient population and conditioning regimens. Traditionally, cardiac performance has been assessed by measuring left ventricular ejection fraction (LVEF) with echocardiography or radionuclide ventriculography. Recently, magnetic resonance imaging (MRI) has been suggested as preferred technique for volume and LVEF estimation. 13 So far, there are no studies using MRI to detect HDT-related cardiotoxicity.
This study was undertaken to prospectively evaluate the very acute effects of high-dose CY on cardiac function assessed by MRI and plasma natriuretic peptide (NTproANP and NT-proBNP) measurements in NHL patients undergoing BEAC chemotherapy.
Patients and methods

Patients and chemotherapy
In total, 17 consecutive adult patients with NHL, who were scheduled to receive HDT supported by ASCT, were studied. Patient characteristics are presented in Tables 1  and 2 . Three patients had pre-existing cardiovascular disease (WHO class II hypertension without left-ventricular hypertrophy). They were treated with angiotensinconverting enzyme inhibitors or calcium channel blockers, but no diuretics or b-blockers were used. One patient had adult-type diabetes mellitus without complications. All patients had earlier received anthracyclines with the cumulative dose 400 mg/m 2 (range 150-500). Mediastinal radiotherapy had been previously administrated to one patient. At the time of HDT, none of the patients suffered from infections or fever and all patients had normal renal function assessed by serum creatinine level. NHL histology was classified according to WHO 14 and the five-graded International Prognostic Index (IPI) was used. Approval for the study was obtained from the local ethical committee and all patients provided written informed consent before the study.
Magnetic resonance imaging
The first MRI study was performed at baseline on day À7 just prior to HDT and the second evaluation was on day À2 just after completing the HDT at 0700 hours. As a result of a technical problem, one patient missed the day À7 study. Two patients suffered from severe nausea on day À2 and were unable to undergo MRI study.
MRI was performed with a 1.5 T clinical MR scanner (Magnetom Vision, Siemens Medical Systems Inc., Erlangen, Germany). A phased array body coil was used as a receiver. Transaxial localiser images were acquired to define left ventricle (LV) and left atrium. Thereafter, cine images were obtained using an ECG-gated gradient echo sequence (TR 50 ms, TE 4.8 ms). LV length was measured in the horizontal long axis plane. Cross-sectional area of the LV myocardium was measured in short axis images at the first and second third of the LV length in end-diastolic and end-systolic images. Left ventricular end-systolic (ESV) and end-diastolic (EDV) volumes were calculated using the modified Simpson's rule. 16, 17 LVEF was calculated using the equation LVEF ¼ ((EDVÀESV)/EDV) Â 100%. 16 All MRI studies and image analysis were performed by one investigator (MH-S). In this study, LVEF decrease X10% from the baseline or LVEFo50% were defined as abnormal.
Natriuretic peptides
Samples for natriuretic peptide measurements were taken at baseline on day À7 prior to HDT and just after completing the HDT on day À2. The blood samples were withdrawn into chilled tubes containing 1.5 mg K2-EDTA/ml blood after the patient had been in the supine position for 30 min at 0080 hours. The whole blood was centrifuged and plasma immediately frozen and stored at À701C. Circulating NT-proBNP (antiserum to NT-proBNP [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] ) and NT-proANP (antiserum to NT-proANP 46-79 ) concentrations were determined by radioimmunoassays as previously described. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A-and B-type natriuretic peptides. 18 In healthy individuals, the NT-proANP concentration is o455 pmol/l and the NT-proBNP concentration o150 pmol/l, with no gender difference. Values exceeding mean þ 2 s.d. of the above values were considered abnormal.
Statistical methods
All calculations were performed with SPSS/PC statistical program (version 11.0, SPSS Inc., Chicago, IL, USA). Paired, two-tailed t-test was performed to compare means. The statistical significance of continues variables in univariate analysis was investigated using Mann-Whitney U-test. The correlations between variables were studied using Spearman's correlation test. The data is expressed as mean7s.e.m. unless otherwise indicated. A P-valueo0.05 was considered as statistically significant.
Results
Altogether 14 patients underwent both MRI studies and all 17 patients were evaluable for natriuretic peptide assessments. There were two patients who suffered from sepsis and died because of multiorgan failure at the intensive care unit shortly after the stem-cell infusion (day þ 7, day þ 10). (Figure 1c) . Only one patient developed a significant decrease in LVEF during the study ( Table 2 , patient 3). However, there was no significant change in mean LVEF (from 51.071.9 to 51.373.1%, P ¼ 0.87) (Figure 1d ). In addition, no change was observed in the left ventricular mass (167.9711.7 to 177.379.2 gr, P ¼ 0.1).
Natriuretic peptides
In two patients (12%) plasma NT-proANP and in three patients (18%) NT-proBNP concentration exceeded the upper limit of reference value at baseline ( Table 2) . The baseline plasma concentration of NT-proANP was 481.17105.5 pmol/l. It increased during BEAC chemotherapy to 1056.67193.1 pmol/l (P ¼ 0.001) (Figure 2a) . The plasma concentration of NT-proBNP was 134.9753.3 pmol/l at baseline and increased to 547.17168.4 pmol/l (P ¼ 0.003) (Figure 2b) .
To examine the possible effects of the intensive fluid infusion during the HDT on natriuretic peptides, a correlation analysis was performed between the natriuretic peptides and weight and serum creatinine level, but no correlation was observed.
Correlations between natriuretic peptides and MRI
The change in NT-proBNP correlated significantly with the change in LVEDV (r ¼ 0.666, P ¼ 0.009) and a borderline correlation was found between the changes in NT-proBNP and LVESV (r ¼ 0.521, P ¼ 0.056). There was also a trend towards a correlation between the increase in plasma concentration of NT-proBNP and the decrease in LVEF from day À7 to À2 (r ¼ À0.479, P ¼ 0.07). However, the correlation between the changes in NT-proANP and left atrial end-systolic area was not significant (P ¼ 0.5).
Discussion
We are not aware of any previous studies investigating the very acute cardiac toxicity of high-dose CY using simultaneous cardiac function and neuroendocrine activation assessments in NHL patients. In this study, the effects of high-dose CY on cardiac function were assessed by MRI and natriuretic peptide measurements. Our novel finding c Adult diabetes mellitus, no medication. The time to death was estimated from the day of stem-cell infusion ¼ day 0.
Very acute cardiac toxicity of BEAC in NHL T Kuittinen et al was that cardiac toxicity characterised by significant enlargement of heart chambers was found immediately after finishing the 4 days high-dose CY treatment. This could not be detected by MRI LVEF measurements, but was clearly mirrored by increased levels of natriuretic peptides. Many methods to assess cardiac function including radionuclide ventriculography (RVG), echocardiocraphy and electrocardiogram have been used to investigate the very acute cardiotoxicity of HDT. However, one retrospective 6 and three prospective studies [7] [8] [9] did not use assessment of neuroendocrine activation in the evaluation of cardiac effects of HDT. In addition, the LVEF measurements by different techniques are not interchangeable. 13 Bellenger et al 13 suggested that MRI is the preferred technique for volume and LVEF estimation, because of its 3D approach for nonsymmetric ventricles and superior image quality. Moreover, it is noninvasive, easy to perform and does not use ionising radiation. 17 We found a strong correlation between the changes in NT-proBNP and in LVEDV. This is logical, since natriuretic peptides are secreted as a result of dilatation of cardiac chambers. The decrease in LVEF also correlated strongly with the increase in LVEDV. BNP elevation has been shown to reflect diastolic dysfunction and may be increased by myocardial stress without necrosis. 19 Surprisingly, we could not detect any significant change either in LVEF or LV mass. LVEF is a marker of cardiac systolic function. This together with the finding of enlargement of cardiac chambers and neurohormonal activation, that Very acute cardiac toxicity of BEAC in NHL T Kuittinen et al is, markers of diastolic function suggests that diastolic dysfunction precedes the development of cardiac systolic dysfunction.
The precise mechanism of high-dose CY-associated cardiac toxicity is unknown. 20 However, it is well known that BNP is primarily released from the ventricles and reflects filling pressure of the left ventricle and ANP is released in response to atrial distension. 21 This is well in line with our finding that dilatation of cardiac chambers correlated with the increase in NT-proBNP. In addition, one possible explanation for cardiotoxicity of high-dose CY is the toxic endothelial damage followed by extravasation of toxic metabolites resulting in interstitial haemorrhage and edema, [2] [3] [4] [5] that is, factors that lead to decrease of myocardial compliance and diastolic dysfunction.
Neuroendocrine activation during or after HDT has been studied earlier. Snowden et al 11 reported that plasma BNP may be used for early detection of cardiac dysfunction during stem-cell transplantation. In their study, however, the peak levels of BNP occurred 1-4 weeks after HDT, which is not very acute finding compared to the significant increase in natriuretic peptides already during the high-dose CY observed in our study. Moreover, Niwa et al 12 showed an elevation on natriuretic peptides very shortly after HDT on day þ 1 and þ 14, but neither peak was predictive of cardiac toxicity. In these pioneer studies, however, the cardiac function tests (RVG or/and Echo) were not performed until weeks after HDT and were not synchronised with natriuretic peptide measurements.
At baseline seven patients had abnormal LVEF. In addition, there were two patients with elevated NTproANP and three patients with elevated NT-proBNP at baseline. These phenomena are obviously due to the previous exposure to anthracyclines. In fact, there are several studies in which natriuretic peptides have been used to assess the anthracycline-related cardiotoxicity. 22, 23 It is obvious that cardiotoxicity mechanisms are different between these two drugs. 8, 24 The additional reasons for increased natriuretic peptides are renal dysfunction, septicaemia and fluid overload. In our study, these causes can be ruled out because no correlation was obtained between natriuretic peptides and renal function and weight.
To conclude, our study shows that high-dose CY results in very acute cardiac toxicity characterised by cardiac dilatation in NHL patients previously treated with anthracyclines. This toxicity can be detected with elevated concentrations of natriuretic peptides (NT-proANP and NT-proBNP) but not with LVEF measurement by MRI. Thus, measurements of natriuretic peptides seem to be more sensitive to detect very acute cardiac toxicity than LVEF measurements. In addition, our findings suggest that acute cardiac toxicity involves diastolic rather than systolic cardiac function. Very acute cardiac toxicity of BEAC in NHL T Kuittinen et al
